Clinical Trial Update: Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating dabigatran etexilate for patients undergoing primary unilateral elective total knee or hip replacement; completed with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arthroplasty Replacement
• Prevention of Venous Thromboembolism

Drugs mentioned

• Dabigatran etexilate (Dabigatran etexilate)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Arthroplasty, Replacement, Prevention of Venous Thromboembolism | Phase 4 | Status: COMPLETED | Results posted: 2014-05-23